Eliana Lara

Mrs. Eliana Lara

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Molecules
Verified
Journal Article
Open access
PDF file
OBOlalla Barreiro-Costa
Olalla Barreiro-Costa
GMGabriela Morales-Noboa
Gabriela Morales-Noboa
PRPatricio Rojas-Silva
Patricio Rojas-Silva
ELEliana Lara
Eliana Lara
Javier SantamaríaJavier Santamaría
Javier Santamaría
JHJorge Heredia-Moya
Jorge Heredia-Moya
This work focuses on the search and development of drugs that may become new alternatives to the commercial drugs currently available for treatment of leishmaniasis. We have designed and synthesized 12 derivatives of bis(spiropyrazolone)cyclopropanes. We then characterized their potential application in therapeutic use. For this, the in vitro biological activities against three eukaryotic models—S. cerevisiae, five cancer cell lines, and the parasite L. mexicana—were evaluated. In addition, cytotoxicity against non-cancerous mammalian cells has been evaluated and other properties of interest have been characterized, such as genotoxicity, antioxidant properties and, in silico predictive adsorption, distribution, metabolism, and excretion (ADME). The results that we present here represent a first screening, indicating two derivatives of bis(spiropyrazolone)cyclopropanes as good candidates for the treatment of leishmaniasis. They have good specificity against parasites with respect to mammalian cells.